[go: up one dir, main page]

SG50624A1 - Methods of producing analgesia and enhancing opiate analgesia - Google Patents

Methods of producing analgesia and enhancing opiate analgesia

Info

Publication number
SG50624A1
SG50624A1 SG1996007083A SG1996007083A SG50624A1 SG 50624 A1 SG50624 A1 SG 50624A1 SG 1996007083 A SG1996007083 A SG 1996007083A SG 1996007083 A SG1996007083 A SG 1996007083A SG 50624 A1 SG50624 A1 SG 50624A1
Authority
SG
Singapore
Prior art keywords
analgesia
methods
producing
enhancing
enhancing opiate
Prior art date
Application number
SG1996007083A
Other languages
English (en)
Inventor
Alan Justice
Tejinder Singh
Chandra Kishor Gohil
Karen Valentino
George Miljanich
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Publication of SG50624A1 publication Critical patent/SG50624A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG1996007083A 1991-12-30 1992-12-30 Methods of producing analgesia and enhancing opiate analgesia SG50624A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81475991A 1991-12-30 1991-12-30

Publications (1)

Publication Number Publication Date
SG50624A1 true SG50624A1 (en) 1998-07-20

Family

ID=25215938

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007083A SG50624A1 (en) 1991-12-30 1992-12-30 Methods of producing analgesia and enhancing opiate analgesia

Country Status (8)

Country Link
US (3) US5587454A (fr)
EP (1) EP0625162B1 (fr)
AT (1) ATE165977T1 (fr)
AU (1) AU689438B2 (fr)
CA (1) CA2151741C (fr)
DE (1) DE69225499T2 (fr)
SG (1) SG50624A1 (fr)
WO (1) WO1993013128A1 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
ES2283671T3 (es) * 1995-06-27 2007-11-01 EISAI R&D MANAGEMENT CO., LTD. Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU6454096A (en) * 1995-07-26 1997-02-26 Warner-Lambert Company Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US6060271A (en) * 1996-02-09 2000-05-09 Cornell Research Foundation, Inc. CDNA fragments corresponding to voltage gated sodium channel genes expressed in peripheral nerve
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6489119B1 (en) * 1996-03-29 2002-12-03 Elan Pharmaceuticals, Inc. Analgesic screening method and composition
AU7080698A (en) 1997-04-25 1998-11-24 Ajinomoto Co., Inc. Novel dihydropyridine derivative
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
CA2224066A1 (fr) * 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides utilises comme analgesiques
EP1043314A4 (fr) 1997-12-22 2001-01-24 Ajinomoto Kk Nouveau derive de dihydropyridine
EP1071707A4 (fr) * 1998-04-16 2004-12-22 Univ Queensland Nouveaux peptides d'omega conotoxine
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
AU778353B2 (en) 1999-01-22 2004-12-02 Cognetix, Inc. Alpha-conotoxin peptides
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP1191021A4 (fr) 1999-06-23 2002-08-07 Ajinomoto Kk Derive de la dihydropyridine
WO2000078730A1 (fr) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Nouveaux derives dihydropyrimidiniques
WO2000078720A1 (fr) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Derive de la dihydropyridine
EP1210100B1 (fr) 1999-08-10 2006-06-14 UAB Research Foundation Procede de traitement de traumatismes cerebraux par des anti-inflammatoires non steroidiens
JP2003533178A (ja) 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
US20030119731A1 (en) * 2000-07-21 2003-06-26 University Of Utah Research Foundation Omega-conopeptides
EP1311283A4 (fr) * 2000-07-21 2004-09-01 Univ Utah Res Found Omega-conopeptides
NZ528771A (en) * 2001-03-23 2007-03-30 Einstein Coll Med Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US7507717B2 (en) * 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
ES2383358T3 (es) * 2002-12-02 2012-06-20 Xenome Ltd Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (zh) 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
US7365050B2 (en) * 2003-08-08 2008-04-29 The Regents Of The University Of California Methods for modulating a drug-related effect or behavior
CA2930900C (fr) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinaisons de ziconotide et d'opioides destinees a reduire la douleur
CA2576826C (fr) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a<sb>2a</sb>
WO2006023272A1 (fr) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
PL1809271T3 (pl) * 2004-09-10 2010-10-29 Newron Pharm Spa Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
WO2007041360A2 (fr) * 2005-09-30 2007-04-12 The Board Of Trustees Of The University Of Illinois Peptides et regulation calcique dans des cellules mammifères
JP5271087B2 (ja) 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
WO2007120972A2 (fr) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Procede permettant de traiter l'anemie a hematies falciformes
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
HRP20180324T8 (hr) 2007-06-15 2019-03-08 Newron Pharmaceuticals S.P.A. Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
MX2011007024A (es) 2008-12-31 2011-09-27 Aedelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
CA2833824C (fr) 2011-06-27 2017-08-29 Newron Pharmaceuticals S.P.A. Derives d'arylalkylaminocarboxamides fluores
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
KR20250026881A (ko) 2013-04-12 2025-02-25 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MA47203A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Inhibiteurs d'antiport à médiation par nhe
CA3127871A1 (fr) 2019-03-01 2020-09-10 Flamel Ireland Limited Compositions de gamma-hydroxybutyrate presentant une pharmacocinetique amelioree a l'etat alimente
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5231011A (en) * 1991-04-18 1993-07-27 University Of Utah Segregated folding determinants for small disulfide-rich peptides

Also Published As

Publication number Publication date
ATE165977T1 (de) 1998-05-15
EP0625162B1 (fr) 1998-05-13
CA2151741A1 (fr) 1993-07-08
HK1013832A1 (en) 1999-09-10
AU689438B2 (en) 1998-04-02
US5587454A (en) 1996-12-24
US5364842A (en) 1994-11-15
DE69225499T2 (de) 1999-02-04
DE69225499D1 (de) 1998-06-18
WO1993013128A1 (fr) 1993-07-08
US5859186A (en) 1999-01-12
EP0625162A1 (fr) 1994-11-23
CA2151741C (fr) 2001-12-11
AU3428093A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
SG50624A1 (en) Methods of producing analgesia and enhancing opiate analgesia
EG20663A (en) Cement treated with high - pressure co2
HUP9900422A3 (en) Novel protein and methods for the production of the same
EP0435787A3 (en) Blended films, structures therefrom, and methods of making and using them
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
MY114039A (en) Simultaneous preparation of caprolactam and hexamethylenediamine
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
EP0630157A3 (fr) Systèmes et méthodes pour le codage de trames alternées de séquences vidéo entrelacées.
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
EP0492612A3 (en) Electrolyzer and method of operating same
EP0693931A4 (fr) Proteines et peptides immunogenes du cancer et procede d&#39;utilisation
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
BG102362A (en) New derivatives of amino acids, their preparation and application
ATE204291T1 (de) Verfahren zur herstellung von peptiden und n- carbamoyl-geschützten peptiden
EP1140144A4 (fr) Procedes et composition de melanges naturels extremement purifies d&#39;interferons de type i derives des leucocytes
MY106352A (en) Hemoregulatory peptides.
EP0449179A3 (en) Shockwave generating system capable of displaying shockwave effective region
GB9516293D0 (en) Novel peptides and their use as vaccines
ZA86338B (en) Novel growth hormone-releasing peptides and method of treating mammals therewith
HU9300489D0 (en) New anti-pathogenic peptides and method for producing them
IL116973A0 (en) Extraction of recombinant proteins
EP0826037A4 (fr) Proteines xylanases des orpinomyces et leurs sequences de codage
ZA929418B (en) Recombinant vaccines and method of producing same.
HU9400467D0 (en) Process for producing and application of peptide agent from apiocrea chrysosperma
EP0667624A3 (fr) Matériau plastique conducteur et méthode pour sa fabrication.